Quick answer
How is a melanotan II stock solution calculated? With three relations: concentration = mass ÷ volume, the dilution equation C1·V1 = C2·V2, and molarity = mass concentration ÷ molar mass. The molar mass follows from the formula C50H69N15O9 on the MT-2 product page, which gives about 1,024 g/mol when summed from standard atomic weights. This page keeps the arithmetic as symbols, with no vial-specific volume tables; the calculator does the numbers. It then describes what the published preclinical work on this analog reports about species, route and readouts, and what a methods section should record. Nothing here recommends a concentration or use. For laboratory research use only; see the melanotan II research overview.
Reconstitution mistakes are rarely chemistry mistakes; they are unit mistakes. A milligram-to-microgram slip or a forgotten dilution step changes a dose-response curve by orders of magnitude and can make a good compound look inactive. This article is the arithmetic and reporting companion to our handling guides: formula first, worked symbolically, with attention to the places where errors enter. A second half summarizes how the published preclinical literature on this analog describes its experimental parameters, so a reader can see what is typically reported. It does not recommend any concentration, and it contains no per-product volume tables, which the calculator provides. The compound is supplied for laboratory research use only; not for human consumption.
The three relations you need
Everything in stock preparation follows from three relations. Let m be the mass of peptide dissolved, V the final volume, C the mass concentration and M the molar mass.
- Mass concentration: C = m / V. To reach a target concentration from a known mass, rearrange to V = m / C.
- Molar concentration: c = C / M, so c (mol/L) = (g/L) ÷ (g/mol). For MT-2 the molar mass can be computed from the formula C50H69N15O9 by summing atomic weights; the result is about 1,024 g/mol.
- Dilution: C1 × V1 = C2 × V2. A stock of concentration C1 is diluted by taking V1 into a final volume V2 to give C2. The dilution factor is C1/C2 = V2/V1.
Two additions make the arithmetic honest. First, the vial label gives the mass of supplied material, and the peptide fraction of that mass (net peptide content) can be below 1 because of counterions and water; if it matters, include it as mpeptide = m × f. Second, the final volume after adding solvent to a powder is slightly more than the volume of solvent added, because the dissolved solid occupies volume; at the concentrations used for peptides the difference is usually negligible, but it should be noted when a precise concentration matters. Our guide on HPLC purity explains why purity and content differ, and the page on reconstitution volume calculations walks through more cases.
| Quantity | Symbol | Unit | Typical slip |
|---|---|---|---|
| Mass | m | mg, µg | Confusing mg with µg (factor of 1,000) |
| Volume | V | mL, µL | Confusing mL with µL (factor of 1,000) |
| Mass concentration | C | mg/mL, µg/mL | Mixing mg/mL and µg/mL in one calculation |
| Molar mass | M | g/mol | Using the monoisotopic mass instead of the average mass |
| Molar concentration | c | mol/L, µM, nM | Forgetting that 1 µM = 10^-6 mol/L |
| Dilution factor | C1/C2 | none | Counting the aliquot volume instead of the final volume |
Serial dilutions and where errors compound
Dose-response series are usually built by serial dilution: each step takes a fixed volume of the previous tube into a fixed volume of diluent. With a transfer volume v into total volume Vstep, each step divides concentration by Vstep / v, and after n steps the concentration is C0 × (v / Vstep)n. Errors compound multiplicatively: a pipetting error of a few percent per step becomes much larger by step six. Using larger transfer volumes, changing tips between steps, and mixing thoroughly each time reduces the drift.
Low concentrations introduce a second problem, loss to surfaces. The literature on plasticware and glassware for peptide work reports that the material of the container affects how much peptide is recovered, so the lowest points of a series are the most vulnerable (Goebel-Stengel et al., 2011). The remedy is to prepare the dilutions immediately before the assay, in the container validated for the peptide, and to verify the stock concentration independently when the result depends on absolute potency. The same reasoning applies to how long a solution is held before use, which is best settled by a stability study in your own system; see how long reconstituted peptides last.
A short checklist for a stock preparation: record the lot; let the sealed vial reach room temperature before opening; note the solvent and its lot; add solvent slowly down the wall; dissolve by gentle swirling, not vigorous shaking; write down the final volume; label with concentration, date and initials; and store as the lab's stability data allow. The stepwise explanation is at how to reconstitute a lyophilized peptide.
Worked symbolic examples
The examples below use symbols so no vial-specific numbers are implied; substitute your own values or use the calculator.
Example 1, target concentration from a known mass. You dissolve mass m and want mass concentration C. Solvent volume is V = m / C. If m is in mg and C in mg/mL, V comes out in mL.
Example 2, molar stock. You want a molar stock c. The mass concentration needed is C = c × M, using M of about 1,024 g/mol for MT-2 from the product-page formula. A 1 mM stock is thus 1,024 mg/L, which equals about 1.02 mg/mL; this is a unit conversion, not a recommendation.
Example 3, a working dilution. From stock C1 you want C2 in a final volume V2. The volume of stock to take is V1 = C2 × V2 / C1, and the diluent volume is V2 − V1.
Example 4, assay-well concentration. If you add a small volume v of a working solution of concentration Cw to a well of total final volume Vwell, the final concentration is Cw × v / Vwell. People often forget that the concentration in the well differs from the concentration in the tube; label both in the lab notebook.
| Goal | Formula | Notes |
|---|---|---|
| Solvent volume for a target concentration | V = m / C | Check units first |
| Mass concentration from molar target | C = c × M | M from the formula, about 1,024 g/mol |
| Stock volume for a working dilution | V1 = C2 × V2 / C1 | Diluent = V2 − V1 |
| Concentration in the assay well | C(well) = Cw × v / V(well) | Report both tube and well values |
| Corrected for peptide content | m(peptide) = m × f | f from analysis; 1.0 if unknown, with the uncertainty noted |
What published preclinical studies report about parameters
The primary literature on this analog is mostly receptor pharmacology, and its abstracts describe design and readouts more often than numerical settings. The following is what the cited abstracts actually state, without recommending anything. The 1980 analog paper reports bioassays in frog skin, activation of mouse melanoma adenylate cyclase and stimulation of mouse melanoma cell tyrosinase, with the analog described as 26 times as potent as alpha-MSH in the adenylate cyclase assay (Sawyer et al., 1980). The 1995 binding study reports expression of MC1, MC3 and MC5 receptors in COS cells and saturable binding of a radiolabeled analog with the Kd values 85.1 pM, 396 pM and 5.05 nM (Schiöth et al., 1995). The 1997 study reports that, in mice, intracerebroventricular administration of the cyclic agonist MTII inhibited feeding in four hyperphagia models and that co-administration of SHU9119 blocked the effect (Fan et al., 1997).
The abstracts do not list the concentrations or amounts used in those experiments. Anyone who needs those parameters must read the full text methods sections, and should regard them as the settings of a specific model, not as general values. For a reader planning an experiment, the more useful takeaway is the structure of what is reported: species and cell system, route of delivery in the animal study (intracerebroventricular in the 1997 paper), the readout, the reference agonist or antagonist, and the control conditions.
| Study | System | Route or format as reported | Readout | Control or comparator |
|---|---|---|---|---|
| Sawyer et al., 1980 | Frog skin; mouse melanoma cells | In vitro bioassay | Skin darkening; adenylate cyclase; tyrosinase | alpha-MSH; heat-alkali-exposed hormone |
| Schiöth et al., 1995 | COS cells expressing MC1, MC3 or MC5 | Radioligand binding | Kd; rank order of peptides | Natural melanocortin peptides |
| Fan et al., 1997 | Mice, four hyperphagia models | Intracerebroventricular | Feeding behavior | SHU9119 co-administration |
A reporting template for your methods section
Reproducibility depends on what is written down. A methods section for work with a reconstituted peptide should state: the compound and sequence; the supplier lot and the form (here, lyophilized powder); the purity as stated on the documentation and how it was documented; the solvent and its grade; the stock concentration and how it was calculated (mass, volume, any peptide-content correction); the storage and holding time before use; the container type; the dilution scheme; the final concentration in the assay; and the controls. The MT-2 product page lists a 10 mg lyophilized powder, at least 98% HPLC purity, stored at 2–8 °C or −20 °C long term and protected from heat, moisture and light; a COA is marked as coming soon there, so cite the documentation that actually exists for your lot, which the COA page describes how to read.
Peptide integrity belongs in the record too. Oxidation of residues such as tryptophan and histidine is a recognized instability route (Li et al., 1995), and formulation reviews describe how handling conditions affect stability (Manning et al., 2010). If the effect size in the study is small, note the time between reconstitution and use. For other research materials, browse the shop.
Frequently asked questions
What are the basic reconstitution formulas?
Concentration C = m/V, molarity c = C/M, and dilution C1V1 = C2V2.
What is the molar mass of MT-2?
About 1,024 g/mol calculated from the product-page formula C50H69N15O9 using average atomic weights.
Why does this page not give a volume table?
Per-vial tables are available from the calculator, which avoids transcription errors; this page teaches the formulas.
Does the label mass equal peptide mass?
Not necessarily. Counterions and water can make the peptide fraction lower than 1, so apply a content factor f when absolute concentration matters.
How do errors compound in serial dilution?
Multiplicatively: after n steps the concentration is C0 × (v/V_step)^n, so small pipetting errors grow with each step.
Why are the lowest dilutions unreliable?
Adsorption to container surfaces takes a larger share of peptide at low concentration (Goebel-Stengel et al., 2011).
What do the published abstracts say about MT-2 parameters?
They report systems and readouts (frog skin, mouse melanoma cells, COS-cell binding, mouse feeding by intracerebroventricular delivery) but not concentrations; those are in the full methods.
Should I copy a concentration from a paper?
Only as a reference for that specific model; potency must be measured in your own system.
What belongs in a methods section?
Lot, form, purity documentation, solvent, stock calculation, holding time, container, dilution scheme, final assay concentration and controls.
What does the product page state about the vial?
A 10 mg lyophilized powder with at least 98% HPLC purity, storage at 2–8 °C or −20 °C long term, COA marked as coming soon.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: Melanotan II Research Models: Cell Lines and Bioassays, Melanotan II Storage: Temperature, Moisture and Light, Melanotan II Structure: Lactam Ring and Synthesis.
References
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
- Schiöth HB, Muceniece R, Wikberg JES, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311-317. doi:10.1016/0922-4106(95)90043-8
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
